Matches in Wikidata for { <http://www.wikidata.org/entity/Q66394763> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q66394763 description "clinical trial" @default.
- Q66394763 description "ensayu clínicu" @default.
- Q66394763 description "klinisch onderzoek" @default.
- Q66394763 description "клінічне випробування" @default.
- Q66394763 name "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)" @default.
- Q66394763 name "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis" @default.
- Q66394763 type Item @default.
- Q66394763 label "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)" @default.
- Q66394763 label "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis" @default.
- Q66394763 prefLabel "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)" @default.
- Q66394763 prefLabel "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis" @default.
- Q66394763 P1050 Q66394763-5419CA25-8060-4B80-AC09-DAC794C35E07 @default.
- Q66394763 P1050 Q66394763-D370C954-CAC6-4731-9065-E7458CBC86AB @default.
- Q66394763 P1132 Q66394763-D6DAE293-9CF4-4F86-A910-392A91212D16 @default.
- Q66394763 P1476 Q66394763-9C3C7538-B49A-4378-8A27-480A69814959 @default.
- Q66394763 P17 Q66394763-1147DB1B-9AA1-422C-A191-6E4D7C15EE40 @default.
- Q66394763 P17 Q66394763-46BA07BD-F2CE-4508-960B-32D3944F0590 @default.
- Q66394763 P17 Q66394763-4E9E3396-818C-4D11-B33A-43D26C257917 @default.
- Q66394763 P17 Q66394763-58D01B28-63E8-4B6B-8862-662B7B690DDD @default.
- Q66394763 P17 Q66394763-60BD6514-133E-44EB-B567-8DC87B052D04 @default.
- Q66394763 P17 Q66394763-76E38F41-FA8D-49AA-B59B-96803F4D81DD @default.
- Q66394763 P17 Q66394763-7B9B8F53-B241-4C4C-8D6E-9566BA6807F8 @default.
- Q66394763 P17 Q66394763-AC08049F-891A-4490-BF7C-9BD7409065E4 @default.
- Q66394763 P17 Q66394763-B4AFD458-B306-4B70-9EF7-1DB78C03AED8 @default.
- Q66394763 P17 Q66394763-B80ED746-2734-4EED-9040-6059F502F29B @default.
- Q66394763 P17 Q66394763-C5D67A94-619D-4C1D-AD8C-2558DA526925 @default.
- Q66394763 P17 Q66394763-E96F8960-FF25-4D08-9699-0C672E3BBB47 @default.
- Q66394763 P17 Q66394763-F113DBE3-7443-40C3-A72F-DAB837DDAB6A @default.
- Q66394763 P17 Q66394763-F3A7E71A-94A2-49AC-97A2-F488A494CBE6 @default.
- Q66394763 P17 Q66394763-F542BA97-0FA7-4B8A-BE36-CC8724359A88 @default.
- Q66394763 P17 Q66394763-FB8DBA88-D281-4287-A370-8219474042CB @default.
- Q66394763 P2899 Q66394763-81226BEE-D26B-4BD4-A899-96DFA3751FF8 @default.
- Q66394763 P3098 Q66394763-CABCEF75-5A75-47E4-AD8A-B949BDCF53E0 @default.
- Q66394763 P31 Q66394763-6FE73DD6-55FC-43B9-8A01-52CA3F549F3C @default.
- Q66394763 P4135 Q66394763-266D6DDB-5A4E-4656-ADAC-42E35199F7B8 @default.
- Q66394763 P580 Q66394763-96F58270-0168-4D67-A631-D6CDBA2BC61F @default.
- Q66394763 P582 Q66394763-767B84A0-DD18-4F48-8A15-02D7ACD7A88E @default.
- Q66394763 P6099 Q66394763-E7E5D620-96A0-4E2F-9D97-B11B89C80429 @default.
- Q66394763 P8363 Q66394763-5A2F4E8A-DFAD-412E-90D9-D33406272A6E @default.
- Q66394763 P859 Q66394763-A3A637E0-05C9-4F8C-B7C1-0704E7751C83 @default.
- Q66394763 P1050 Q140067 @default.
- Q66394763 P1050 Q8277 @default.
- Q66394763 P1132 "+681" @default.
- Q66394763 P1476 "An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment" @default.
- Q66394763 P17 Q142 @default.
- Q66394763 P17 Q145 @default.
- Q66394763 P17 Q183 @default.
- Q66394763 P17 Q191 @default.
- Q66394763 P17 Q20 @default.
- Q66394763 P17 Q27 @default.
- Q66394763 P17 Q29 @default.
- Q66394763 P17 Q31 @default.
- Q66394763 P17 Q33 @default.
- Q66394763 P17 Q34 @default.
- Q66394763 P17 Q35 @default.
- Q66394763 P17 Q38 @default.
- Q66394763 P17 Q39 @default.
- Q66394763 P17 Q408 @default.
- Q66394763 P17 Q43 @default.
- Q66394763 P17 Q55 @default.
- Q66394763 P2899 "+18" @default.
- Q66394763 P3098 "NCT02861014" @default.
- Q66394763 P31 Q30612 @default.
- Q66394763 P4135 "+55" @default.
- Q66394763 P580 "2016-09-09T00:00:00Z" @default.
- Q66394763 P582 "2021-01-01T00:00:00Z" @default.
- Q66394763 P6099 Q42824827 @default.
- Q66394763 P8363 Q78089383 @default.
- Q66394763 P859 Q212646 @default.